GlobeNewswire Inc | Mar 4, 2021 01:00AM EST

March 04, 2021

FDA accepts Dupixent (dupilumab) for review in children with moderate-to-severe asthma

-- Submission supported by data demonstrating Dupixent significantly reduced severe asthma attacks and is the only biologic to improve lung function in children aged 6 to 11 years with asthma in a randomized Phase 3 trial, while also further adding to the well-established safety profile of Dupixent -- Dupixent has the potential to be a best-in-class treatment option in this younger population of children aged 6 to 11 -- Acceptance represents another milestone in the development of Dupixent in addressing diseases driven by type 2 inflammation

PARIS and TARRYTOWN, N.Y. March 4, 2021 - The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma. Dupixent is currently approved as an add-on treatment for patients with uncontrolled moderate-to-severe asthma aged 12 and older with elevated eosinophils or oral corticosteroid dependent asthma. The target action date for the FDA decision is October 21, 2021 and the EU regulatory submission for children aged 6 to 11 years with asthma is planned for Q1 2021.

In the U.S., approximately 75,000 children aged 6 to 11 years are living with uncontrolled moderate-to-severe asthma, which can carry a significant burden for children and their families. Despite treatment with current standard-of-care inhaled corticosteroids and bronchodilators, these children can still experience coughing, wheezing, and difficulty breathing. They are also at risk for life-threatening severe asthma attacks that can lead to hospitalization and emergency room visits, and may require the use of systemic corticosteroids which carry significant risks when used long term. Uncontrolled moderate-to-severe asthma can impair lung function, and can interfere with day-to-day activities, such as sleeping, attending school and playing sports.

The sBLA is supported by data that include pivotal Phase 3 results evaluating the efficacy and safety of Dupixent in addition to standard-of-care maintenance therapy in children with moderate-to-severe asthma with type 2 inflammation, characterized by elevated blood eosinophil levels and/or raised fractional exhaled nitric oxide (FeNO) levels. In the trial, Dupixent significantly reduced severe asthma attacks and rapidly improved lung function within two weeks in children aged 6 to 11 years. Safety results were generally consistent with the well-established safety profile of Dupixent in the approved indication for patients aged 12 and older with moderate-to-severe asthma. Adverse events in the Phase 3 trial that were more commonly observed with Dupixent included injection site reactions, viral upper respiratory tract infections and eosinophilia. Detailed results from this Phase 3 trial will be published later this year.

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), atopic dermatitis and eosinophilic esophagitis.

About Dupixent

Dupixent is approved in the U.S. to treat patients aged 6 years and older with moderate-to-severe atopic dermatitis that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies; for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in patients aged 12 years and older whose asthma is not controlled with their current asthma medicines; and for use with other medicines for the maintenance treatment of CRSwNP in adults whose disease is not controlled.

Outside of the U.S., Dupixent is approved for specific patients with moderate-to-severe atopic dermatitis and certain patients with asthma in a number of other countries around the world, including the EU and Japan. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP. Across all approved indications globally, more than 200,000 patients have been treated with Dupixent.

Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home by self-administration after training by a healthcare professional. In children younger than 12 years of age, Dupixent should be administered by a caregiver.

Dupilumab development program

To date, dupilumab has been studied in more than 10,000 patients across 50 clinical trials in various chronic diseases driven by type 2 inflammation.

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including pediatric asthma (6 to 11 years of age, Phase 3), chronic obstructive pulmonary disease with evidence of type 2 inflammation (Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), eosinophilic esophagitis (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), chronic inducible urticaria-cold (Phase 3), chronic rhinosinusitis without nasal polyposis (Phase 3), allergic fungal rhinosinusitis (Phase 3) and food allergies (Phase 2). These potential uses are under clinical investigation, and the safety and efficacy of dupilumab in these conditions have not been fully evaluated by any regulatory authority. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.



About Sanofi

Sanofi is dedicated to supporting people through their health challenges. Weare a global biopharmaceutical company focused on human health. We preventillness with vaccines, provide innovative treatments to fight pain and easesuffering. We stand by the few who suffer from rare diseases and the millionswith long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transformingscientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life



Sanofi Investor Relations Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton

Sanofi Media Relations Contact Sally BainTel: +1 781-264-1091 Sanofi Investor Relations Contacts NorthSally.Bain@sanofi.com America Felix Lauscher Fara Berkowitz Suzanne Greco



Sanofi IR main line: Tel: +33 (0)1 53 77 45 45 investor.relations@sanofi.com https://www.sanofi.com/en/investors/contact



Regeneron Media Relations Contact Regeneron Investor Relations ContactSharon Chen Mark HudsonTel: +1 914-847-1546 Tel: +1 914-847-3482Sharon.Chen@regeneron.com Mark.Hudson@regeneron.com

Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in thePrivate Securities Litigation Reform Act of 1995, as amended. Forward-lookingstatements are statements that are not historical facts. These statementsinclude projections and estimates regarding the marketing and other potentialof the product, or regarding potential future revenues from the product.Forward-looking statements are generally identified by the words ?expects?,?anticipates?, ?believes?, ?intends?, ?estimates?, ?plans? and similarexpressions. Although Sanofi?s management believes that the expectationsreflected in such forward-looking statements are reasonable, investors arecautioned that forward-looking information and statements are subject tovarious risks and uncertainties, many of which are difficult to predict andgenerally beyond the control of Sanofi, that could cause actual results anddevelopments to differ materially from those expressed in, or implied orprojected by, the forward-looking information and statements. These risks anduncertainties include among other things, unexpected regulatory actions ordelays, or government regulation generally, that could affect the availabilityor commercial potential of the product, the fact that product may not becommercially successful, the uncertainties inherent in research anddevelopment, including future clinical data and analysis of existing clinicaldata relating to the product, including post marketing, unexpected safety,quality or manufacturing issues, competition in general, risks associated withintellectual property and any related future litigation and the ultimateoutcome of such litigation, and volatile economic and market conditions, andthe impact that COVID-19 will have on us, our customers, suppliers, vendors,and other business partners, and the financial condition of any one of them, aswell as on our employees and on the global economy as a whole. Any materialeffect of COVID-19 on any of the foregoing could also adversely impact us. Thissituation is changing rapidly and additional impacts may arise of which we arenot currently aware and may exacerbate other previously identified risks. Therisks and uncertainties also include the uncertainties discussed or identifiedin the public filings with the SEC and the AMF made by Sanofi, including thoselisted under ?Risk Factors? and ?Cautionary Statement Regarding Forward-LookingStatements? in Sanofi?s annual report on Form 20-F for the year ended December31, 2019. Other than as required by applicable law, Sanofi does not undertakeany obligation to update or revise any forward-looking information orstatements.

Regeneron Forward-Looking Statements and Use of Digital MediaThis press release includes forward-looking statements that involve risks anduncertainties relating to future events and the future performance of RegeneronPharmaceuticals, Inc. (?Regeneron? or the ?Company?), and actual events orresults may differ materially from these forward-looking statements. Words suchas ?anticipate,? ?expect,? ?intend,? ?plan,? ?believe,? ?seek,? ?estimate,?variations of such words, and similar expressions are intended to identify suchforward-looking statements, although not all forward-looking statements containthese identifying words. These statements concern, and these risks anduncertainties include, among others, the impact of SARS-CoV-2 (the virus thathas caused the COVID-19 pandemic) on Regeneron?s business and its employees,collaborators, and suppliers and other third parties on which Regeneron relies,Regeneron?s and its collaborators? ability to continue to conduct research andclinical programs, Regeneron?s ability to manage its supply chain, net productsales of products marketed or otherwise commercialized by Regeneron and/or itscollaborators (collectively, ?Regeneron?s Products?), and the global economy;the nature, timing, and possible success and therapeutic applications ofRegeneron?s Products and product candidates being developed by Regeneron and/orits collaborators (collectively, ?Regeneron?s Product Candidates?) and researchand clinical programs now underway or planned, including without limitationDupixent^ (dupilumab) as an add-on treatment for children aged 6 to 11 yearswith uncontrolled moderate-to-severe asthma characterized by raised bloodeosinophil levels and/or raised fractional exhaled nitric oxide (FeNO) levels(?Pediatric Asthma?); the likelihood, timing, and scope of possible regulatoryapproval and commercial launch of Regeneron?s Product Candidates and newindications for Regeneron?s Products, such as dupilumab for the treatment ofPediatric Asthma, chronic obstructive pulmonary disease, pediatric atopicdermatitis, eosinophilic esophagitis, bullous pemphigoid, prurigo nodularis,chronic spontaneous urticaria, food and environmental allergies, and otherpotential indications; uncertainty of market acceptance and commercial successof Regeneron?s Products and Regeneron?s Product Candidates and the impact ofstudies (whether conducted by Regeneron or others and whether mandated orvoluntary), including the studies discussed or referenced in this pressrelease, on the commercial success of Regeneron?s Products and Regeneron?sProduct Candidates; safety issues resulting from the administration ofRegeneron?s Products and Regeneron?s Product Candidates in patients, includingserious complications or side effects in connection with the use of Regeneron?sProducts and Regeneron?s Product Candidates in clinical trials; determinationsby regulatory and administrative governmental authorities which may delay orrestrict Regeneron?s ability to continue to develop or commercializeRegeneron?s Products and Regeneron?s Product Candidates; ongoing regulatoryobligations and oversight impacting Regeneron?s Products, research and clinicalprograms, and business, including those relating to patient privacy; theavailability and extent of reimbursement of Regeneron?s Products fromthird-party payers, including private payer healthcare and insurance programs,health maintenance organizations, pharmacy benefit management companies, andgovernment programs such as Medicare and Medicaid; coverage and reimbursementdeterminations by such payers and new policies and procedures adopted by suchpayers; competing drugs and product candidates that may be superior to, or morecost effective than, Regeneron?s Products and Regeneron?s Product Candidates;the extent to which the results from the research and development programsconducted by Regeneron and/or its collaborators may be replicated in otherstudies and/or lead to advancement of product candidates to clinical trials,therapeutic applications, or regulatory approval; the ability of Regeneron tomanufacture and manage supply chains for multiple products and productcandidates; the ability of Regeneron?s collaborators, suppliers, or other thirdparties (as applicable) to perform manufacturing, filling, finishing,packaging, labeling, distribution, and other steps related to Regeneron?sProducts and Regeneron?s Product Candidates; unanticipated expenses; the costsof developing, producing, and selling products; the ability of Regeneron tomeet any of its financial projections or guidance and changes to theassumptions underlying those projections or guidance; the potential for anylicense, collaboration, or supply agreement, including Regeneron's agreementswith Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or theirrespective affiliated companies, as applicable), to be cancelled or terminated;and risks associated with intellectual property of other parties and pending orfuture litigation relating thereto (including without limitation the patentlitigation and other related proceedings relating to EYLEA^ (aflibercept)Injection, Dupixent, Praluent^ (alirocumab), and REGEN-COV^TM (casirivimab andimdevimab)), other litigation and other proceedings and governmentinvestigations relating to the Company and/or its operations, the ultimateoutcome of any such proceedings and investigations, and the impact any of theforegoing may have on Regeneron's business, prospects, operating results, andfinancial condition. A more complete description of these and other materialrisks can be found in Regeneron?s filings with the U.S. Securities and ExchangeCommission, including its Form 10-K for the year ended December 31, 2020. Anyforward-looking statements are made based on management?s current beliefs andjudgment, and the reader is cautioned not to rely on any forward-lookingstatements made by Regeneron. Regeneron does not undertake any obligation toupdate (publicly or otherwise) any forward-looking statement, including withoutlimitation any financial projection or guidance, whether as a result of newinformation, future events, or otherwise.

Regeneron uses its media and investor relations website and social mediaoutlets to publish important information about the Company, includinginformation that may be deemed material to investors. Financial and otherinformation about Regeneron is routinely posted and is accessible onRegeneron's media and investor relations website ( http://newsroom.regeneron.com) and its Twitter feed ( http://twitter.com/regeneron).

Attachment

-- Press Release